All relevant data are within the manuscript and its Supporting Information files.

Background {#sec005}
==========

For many years human immunodeficiency virus (HIV) has been one of the most heavily researched infectious diseases, and now, controlling HIV is beginning to look achievable \[[@pone.0231388.ref001]\]. Improved methods of HIV prevention and control such as pre-exposure prophylaxis (PrEP), anti-retroviral therapy (ART) and even voluntary medical male circumcision (VMMC) are at the forefront of health policy recommendations \[[@pone.0231388.ref001]--[@pone.0231388.ref004]\]. If these interventions are effectively implemented at the population level, they may substantially reduce HIV transmission and eventually end the HIV epidemic. Many modelling studies have attempted to quantify the impact of these interventions on HIV prevalence and related mortality in a range of settings \[[@pone.0231388.ref005]--[@pone.0231388.ref010]\].

HIV positivity has been linked to higher rates of human papillomavirus (HPV) acquisition, and, among those infected with HPV, the presence of an HIV co-infection is known to reduce the likelihood of HPV clearance and regression of pre-cancerous lesions, and, increase the risk of progression \[[@pone.0231388.ref011]\]. For this reason, modelling studies evaluating cervical cancer prevention policies are increasingly considering, either directly or indirectly, the impacts of endemic HIV in relevent settings \[[@pone.0231388.ref007], [@pone.0231388.ref012], [@pone.0231388.ref013]\].

Methods of HIV control may have a substantial impact not only on prevalence and deaths due to HIV, but also on HPV prevalence and subsequently cervical cancer incidence and mortality rates \[[@pone.0231388.ref011], [@pone.0231388.ref014]\]. In particular, male circumcision has been shown to reduce the risk of HIV-1 acquisition in heterosexual men over a time-period of 18--24 months by at least 60%, and, reduce HPV prevalence among heterosexual men by 63% \[[@pone.0231388.ref015]--[@pone.0231388.ref019]\]. Reductions in male HIV and HPV prevalence then results in women also experiencing less HIV and oncogenic HPV infection, and subsequently, less cervical cancer \[[@pone.0231388.ref016], [@pone.0231388.ref020]\]. A global ecological analysis classifying VMMC into high (\>80%), intermediate (20--80%) and low (\<20%) prevalence has reported that for each categorical shift in VMMC prevalence, cervical cancer incidence was reduced by 3.65 (0.54--6.76) cases per 100,000 women per year \[[@pone.0231388.ref021]\].

The United Republic of Tanzania has a high burden of both HIV and cervical cancer. It was estimated that in 2018, 5.5% of Tanzanian women aged 15--49 years were living with HIV \[[@pone.0231388.ref022]\], while the incidence of cervical cancer was among the highest globally, at 59.1 cases diagnosed per 100,000 women (9,771 cervical cancers detected) in 2018 \[[@pone.0231388.ref023]\]. The 2018 incidence rates of cervical cancer in Southern Africa and Eastern Africa were 43.1 cases per 100,000 women per year, and 40.1 cases per 100,000 women per year, respectively \[[@pone.0231388.ref023]\]. Tanzania is within the sub-Saharan African region, which in 2018 contained 53% of all people living with HIV globally and had an estimated HIV prevalence among adults aged 15--49 years of 7% \[[@pone.0231388.ref024], [@pone.0231388.ref025]\]. The two main interventions against HIV currently in place in Tanzania are ART and VMMC, which are both being actively scaled up \[[@pone.0231388.ref026]\]; while the Tanzanian Ministry of Health recommends PrEP use for those at significant risk of HIV acquisition, scale up of access to PrEP has been limited \[[@pone.0231388.ref027]\]. In light of Tanzania's high burden of cervical cancer and the known impact of HIV, it is important to assess the impact of HIV control interventions that are currently being scaled up (ART and VMMC) or considered (PrEP) on not only HIV incidence and prevalence, but also rates of cervical cancer incidence and mortality. This exercise will provide important context to understanding the impact of scaling up prevention and treatment strategies to achieve cervical cancer elimination targets. Furthermore, while there exists significant variation in national laws pertaining to sexual identity and orientation, sex-work, and access to contraception across the African continent which affect local rates of sexually transmitted diseases \[[@pone.0231388.ref024]\], the relative impact of HIV interventions on cervical cancer incidence rates in Tanzania is likely to be broadly representative of the region.

The aim of this analysis, therefore, was to quantify the effect of HIV control actions to date on cervical cancer incidence and mortality in terms of rates, cancer diagnoses and lives saved, and to predict future cervical cancer incidence and mortality rates in Tanzania, in the context of scaled-up HIV control interventions.

Methods {#sec006}
=======

Model overview and parameterisation {#sec007}
-----------------------------------

A detailed deterministic transmission-dynamic compartment model was developed to concurrently simulate the transmission and natural history of HIV, HPV 16/18, HPV 31/33/45/52/58 (referred to as HPV H5) and other oncogenic high-risk HPV types (referred to as HPV OHR) in the United Republic of Tanzania. While there are a range of transmission modalities for HIV and HPV, this platform simulates heterosexual transmission only (a simplifying assumption), as this is the dominant mode of transmission for both HIV and HPV in sub-Saharan Africa \[[@pone.0231388.ref028], [@pone.0231388.ref029]\]. The platform can simulate dual HIV and HPV infections, as well as infections with multiple HPV types, with and without ART. The model incorporates comprehensive demographic, sexual behaviour and natural history assumptions, and accounts for VMMC, ART and PrEP. The simulated population includes males, females and a separate subgroup of female commercial sex-workers (which females may be hired into or retire from), from ages 5 to 79 years, stratified by sex, five-year age group, sexual activity level, HIV and HPV infection, and treatment status. This model is comprised of 11,022,480 compartments, where simulated populations move between the states described in [Table 1](#pone.0231388.t001){ref-type="table"}. Note that all persons in the simulated population are categorised by some combination of attributes: sex/career, age, sexual activity level, HIV infection status and natural history, HIV treatment status (note that no HIV negative individuals are treated with the exception of PReP which may be provided prophylactically for HIV prevention in HIV negative individuals), HPV 16/18 infection status and natural history, HPV H5 infection status and natural history, HPV OHR infection status and natural history and cervical cancer detection status and treatment. Note that only women can progress from HPV infections to cervical pre-cancer, and only women with cervical cancer may have cancer detected. The model implementation utilised for this analysis runs on a quarterly timestep (13 weeks).

10.1371/journal.pone.0231388.t001

###### Model compartments exist for the cartesian product of sets (A) to (I).

![](pone.0231388.t001){#pone.0231388.t001g}

  SEX/CAREER (A)      AGE (YEARS) (B)                      SEXUAL ACTIVITY LEVEL (C)              HIV NATURAL HISTORY (D)                HIV ART STATUS (E)                     HPV 16/18 NATURAL HISTORY (F)               HPV H5 NATURAL HISTORY (G)   HPV OHR NATURAL HISTORY (H)                        CERVICAL CANCER DETECTION AND TREATMENT (I)
  ------------------- ------------------------------------ -------------------------------------- -------------------------------------- -------------------------------------- ------------------------------------------- ---------------------------- -------------------------------------------------- ----------------------------------------------------
  Male                5--9                                 General population sexual activity     Immune (PrEP)                          Untreated                              Immune (HPV vaccine)                        Immune (HPV vaccine)         Immune (HPV vaccine)                               No cervical cancer detected
  Female              10--14                               Elevated sexual activity               Susceptible                            ART (no viral suppression)             Susceptible                                 Susceptible                  Susceptible                                        Symptomatically detected localised cervical cancer
  Female sex-worker   15--19                                                                      Acute infection                        ART (viral suppression)                HPV 16/18 infection                         HPV 16/18 infection          HPV 16/18 infection                                Symptomatically detected regional cervical cancer
                      20--24                               Stage 1 (WHO clinical)                                                        CIN 1                                  CIN 1                                       CIN 1                        Symptomatically detected distant cervical cancer   
  ...                 Stage 2 (WHO clinical)               CIN 2                                  CIN 2                                  CIN 2                                  Screen detected localised cervical cancer                                                                                   
  60--64              Stage 3 (WHO clinical)               CIN 3                                  CIN 3                                  CIN 3                                  Screen detected regional cervical cancer                                                                                    
  65--69              Stage 4 / AIDS (WHO clinical)        Undetected localised cervical cancer   Undetected localised cervical cancer   Undetected localised cervical cancer   Screen detected distant cervical cancer                                                                                     
  70--74                                                   Undetected regional cervical cancer    Undetected regional cervical cancer    Undetected regional cervical cancer    Cervical cancer survivor                                                                                                    
  75--79              Undetected distant cervical cancer   Undetected distant cervical cancer     Undetected distant cervical cancer                                                                                                                                                                        

The model's input parameters were specified primarily using empirical data; however, some parameters, particularly those unobservable or informed by survey data, were found through calibration using a trust region reflective algorithm. The parameter inputs found through calibration were the per-timestep volumes of sex-, age- and activity-group specific high-risk sexual contacts, the degree of age-assortative sexual mixing, annual fluctuations in population-level risk aversive behaviour, and the relative per-sex-act probability of HIV acquisition for females compared to males. These inputs were calibrated to estimated sex-specific HIV prevalence over time, as well as annual rates of new HIV infections obtained from UNAIDS \[[@pone.0231388.ref022], [@pone.0231388.ref030], [@pone.0231388.ref031]\]. Note that different groupings in the presented age-range of calibration/validation results are due to variation in reported age-ranges in the observed data.

### Demography {#sec008}

Population demography encompasses compartments for sex/career (male, female, commercial sex-worker), age (five-year age-groups from 5--9 to 75--79 years) and sexual activity level (age- and sex-specific rates of propensity towards sexual risk-taking). The demography module accounts for population ageing, recruitment, natural mortality and assigns risk groups. The youngest simulated age group is 5--9 years, therefore recruitment represents the number of children born who survive to age five, and accounts for the age- and year-specific fertility rates of the simulated female population, as well as infant mortality. The per-timestep probability of any individual ageing to the next five-year age-group is calculated using the number of single-year ages in the age group, and the number of model iterations per year. For example, $\frac{1}{5}$ of individuals in the 10--14 year age-group turn 15 in any given year, and since there are four timesteps simulated per year, the probability of ageing from the 10--14 year group to the 15--19 year group is $\frac{1}{5} \times \frac{1}{4} = 0.05$. In calculating recruitment, annual fertility rates were sourced from the World Bank using the median fertility variant \[[@pone.0231388.ref032]\], whereas data on maternal age at birth was sourced from the United Republic of Tanzania Ministry of Finance and is based on the 2012 census \[[@pone.0231388.ref033]\]. The simulated population is subject to an age-specific probability of death resulting from any cause other than HIV or cervical cancer (other cause mortality). Age-and-year-specific mortality rates were derived using the projected year-on-year life tables reported by the United Nations Population Division, adjusted for HIV and cervical cancer mortality \[[@pone.0231388.ref034]\]. Finally, the demography module re-distributes the simulated population into two sex- and age-specific sexual activity groups (high-activity and general-activity) and simulates the recruitment of women into a career of commercial sex work, and, their eventual retirement. The initial age-distribution was based on the 1960 Tanzanian population \[[@pone.0231388.ref035]\], with a sex ratio of 1 male to 1.03 females, based on data from the World Bank \[[@pone.0231388.ref036]\].

### Force of infection {#sec009}

The model simulates HIV and HPV transmission between sexual partners, including interactions between commercial sex workers (CSWs) and their male clients. The population is compartmentalised into 'high activity' and 'general activity' sexual activity groups, which differ in their assumed number of sexual contacts per timestep. The number of sexual interactions per time-step implicitly accounts for new partners, the per-partnership frequency of sex, and relationship type (casual or monogamous). An age-dependent proportion of the female population were assumed to be CSWs, with an age-specific probability of seeking commercial sex defined for males. Furthermore, CSWs engage in both personal and commercial sexual interactions, with a pre-defined age-specific client volume per timestep.

The model platform calculates the sex- and age-specific per-timestep force of infection using age-specific partnership preferences, sexual activity group, HIV/HPV prevalence among sex partners, the per-sex-act probability of pathogen transmission (stratified by disease stage where applicable) and uptake of preventative interventions such as condom use (specified separately for commercial sex and general partnerships), VMMC prevalence and ART use. For example, the force of infection for HIV for a male aged *a* in sexual activity group *r* at time *t* is calculated using [Eq 1](#pone.0231388.e003){ref-type="disp-formula"}. $$\begin{matrix}
{\Lambda_{M}^{HIV}\left( a,r,t \right) = {c_{M}\left( a,r,t \right)\left( 1 - \kappa_{HIV}\left( t \right) \right)\left( 1 - \upsilon_{HIV}\left( t \right) \right){\sum_{i}\left( {\sum_{Tx}{\left( \rho_{M}\left( a \right) \bullet T_{FM}^{HIV{(Tx)}}\left( i \right) \right)Ι_{F}^{HIV{(Tx)}}\left( i,t \right)}} \right)} + \lambda_{M}^{HIV}\left( a,r,t \right)\#}} \\
\end{matrix}$$ *c*~*M*~(*a*, *r*, *t*) denotes the average number of sexual contacts for a male aged *a* in sexual-activity group *r* at time *t*; *k*~*HIV*~(*t*) denotes the per-sex-act probability that a condom is worn and prevents HIV acquisition; *υ*~*HIV*~(*t*) denotes the probability that the male has undergone VMMC and the per-sex act-probability that this prevents HIV acquisition; *i* is the stage of HIV disease among female sex-partners; *ρ*~*M*~(*a*) is a vector of the distribution of preferences for female partners of each age-group for males aged *a* (vector over all ages summing to unity); $T_{FM}^{HIV(Tx)}\left( i \right)$ is the HIV-stage-specific per sex-act female-to-male transmission probability for females with treatment status *Tx*; $\left( a \right) \bullet T_{FM}^{HIV{(Tx)}}$ refers to the dot product between vectors *ρ*~*M*~(*a*) and $T_{FM}^{HIV{(Tx)}}$; $Ι_{F}^{HIV(Tx)}\left( i,t \right)$ is a vector specifying the age-specific probability of a female being HIV positive (simulated), stage *i*, and with treatment status *Tx* and time *t*; and finally, $\lambda_{M}^{HIV}\left( a,r,t \right)$ is the probability of acquiring an HIV infection from a commercial sex worker. Note that $$\begin{matrix}
{\lambda_{M}^{HIV}\left( a,r,t \right) = {\varsigma_{M}\left( a,r,t \right)\left( 1 - \kappa_{HIV}\left( t \right) \right)\left( 1 - \upsilon_{HIV}\left( t \right) \right){\sum\limits_{i}\left( {\sum\limits_{Tx}{\left( \rho_{M}\left( a \right) \bullet T_{FM}^{HIV{(Tx)}}\left( i \right) \right)Ι_{CSW}^{HIV{(Tx)}}\left( i,t \right)}} \right)}\#}} \\
\end{matrix}$$ Where *ς*~*M*~(*a*, *r*, *t*) denotes the average number of commercial sexual contacts assumed for a male aged *a* in sexual risk group *r* at time *t*; and, $Ι_{CSW}^{HIV(Tx)}\left( i,t \right)$ is a vector specifying the age-specific probability of a commercial sex worker being HIV positive, stage *i* and with treatment status *Tx* at time *t*.

The HPV 16/18 force of infection for a high activity male aged *a* at time *t* is calculated in a similar way but simplified by the assumption that the probability of HPV transmission is fixed irrespective of HPV disease stage. That is, $$\begin{matrix}
{\Lambda_{M}^{HPV_{1618}}\left( a,r,t \right) = {c_{M}\left( a,r,t \right)\left( 1 - \kappa_{HPV}\left( t \right) \right)\left( 1 - \upsilon_{HPV}\left( t \right) \right)T_{FM}^{HPV_{1618}}\left( \rho_{M}\left( a \right) \bullet Ι_{F}^{{HPV}_{1618}}\left( t \right) \right) + \lambda_{M}^{HPV_{1618}}\left( a,r,t \right)\#}} \\
\end{matrix}$$ *k*~*HPV*~(*t*) denotes the per-sex-act probability that a condom is worn and prevents HPV acquisition; *υ*~*HPV*~(*t*) denotes the probability that the male has undergone VMMC and the per-sex act-probability that this prevents HPV acquisition; $T_{FM}^{HPV_{1618}}$ is the per sex-act female-to-male HPV16/18 transmission probability; and, $Ι_{F}^{{HPV}_{1618}}\left( t \right)$ is a vector specifying the age-specific probability of a female being HPV 16/18 positive. Additionally, $$\begin{matrix}
{\lambda_{M}^{HPV_{1618}}\left( a,r,t \right) = {\varsigma_{M}\left( a,r,t \right)\left( 1 - \kappa_{HPV}\left( t \right) \right)\left( 1 - \upsilon_{HPV}\left( t \right) \right)T_{FM}^{HPV_{1618}}\left( \rho_{M}\left( a \right) \bullet Ι_{CSW}^{{HPV}_{1618}}\left( t \right) \right)\#}} \\
\end{matrix}$$

Equations specifying the force of infection for HPV H5 and HPV OHR in males and females are similar to the above and are provided in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"}. Detailed input parameter assumptions relevant to the calculation of force of infection are also described in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"} (see equations s1-s12).

### Disease natural history {#sec010}

Disease progression for HIV infection is governed by the following state diagram ([Fig 1](#pone.0231388.g001){ref-type="fig"}), where specific progression rates are dependent on the current stage of disease and treatment status.

![State-space diagram for HIV disease progression.\
Note that viral suppression was assumed to halt disease progression and that all states are subject to other cause mortality.](pone.0231388.g001){#pone.0231388.g001}

The natural history of HIV infection progresses from acute HIV infection though four clinical disease stages. These stages are aligned with the World Health Organisation (WHO) Clinical Staging of HIV/AIDS for Adults and Adolescents \[[@pone.0231388.ref037]\], and are defined in terms of patient symptoms. Input parameters specifying HIV progression rates in the model are described in [Table 2](#pone.0231388.t002){ref-type="table"}.

10.1371/journal.pone.0231388.t002

###### Average length of time spent in each disease stage, and the probability of HIV-death for each HIV disease stage.

![](pone.0231388.t002){#pone.0231388.t002g}

                                                                                                                                                                     Acute infection   WHO clinical stage 1   WHO clinical stage 2   WHO clinical stage 3   WHO clinical stage 4 (AIDS)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------- ---------------------- ---------------------- ---------------------- -----------------------------
  **Average length of time spent in HIV disease stage**[^1^](#t002fn001){ref-type="table-fn"}                                                                        \< 3 months       1 year 6 months        1 year 3 months        6 years 6 months       1 year 3 months
  **Per-timestep probability of HIV-death while in each disease stage**[^2^](#t002fn002){ref-type="table-fn"} **for ages 15--49 years and ages 50+, respectively**   3%, 5%            2%, 5%                 4%, 4%                 1%, 2%                 14%, 27%

^1.^ As published in Palk et al 2018 (Sci Rep) \[[@pone.0231388.ref038]\];

^2.^ As published in Tan et al \[[@pone.0231388.ref011]\].

The model platform accounts for the detailed and well-understood natural history of HPV. Disease progression and regression for HPV infection are governed as per [Fig 2](#pone.0231388.g002){ref-type="fig"}, where specific progression rates are dependent on HPV type, age, disease stage, HIV positivity and ART treatment status. HPV types 16/18 are known to be more aggressive than other oncogenic HPV types, with elevated disease progression rates and reduced regression rates. Women with an HIV co-infection also experience more aggressive HPV infections; however, viral suppression through ART can help to mitigate this \[[@pone.0231388.ref011]\]. The model contains interacting compartments for all HPV susceptibility/infection and natural history states for HPV types 16/18, HPV H5 and HPV OHR. These stages are described in [Table 3](#pone.0231388.t003){ref-type="table"}, and their interactions are summarised in [Fig 2](#pone.0231388.g002){ref-type="fig"}, which describes the state transitions possible from each state at the start of a new timestep, including the case where no state transition is made.

![State space diagram for the natural history of HPV and cervical cancer carcinogenesis; note that all compartments are subject to natural mortality, and detected cancer (grey) compartments are subject to stage-specific cervical cancer mortality and survival rates; CIN = cervical intraepithelial neoplasia; CC = cervical cancer.](pone.0231388.g002){#pone.0231388.g002}

10.1371/journal.pone.0231388.t003

###### List and description of HPV transmission and natural history compartments.
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  Compartment name                         Description
  ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccinated                               Vaccinated individuals are unable to become infected with HPV. Note that this model iteration does not assume any HPV vaccination occurs.
  Susceptible                              Individuals are recruited into this compartment.
  Naturally immune                         Once clearing an HPV infection, some individuals retain temporary natural immunity.
  HPV infected                             Susceptible individuals may become infected with HPV. Initial model conditions specify a small number of HPV infected individuals to start the simulation.
  CIN 1                                    Cervical intraepithelial neoplasia (abbreviated as CIN) stage 1 is a low-grade pre-cancerous lesion.
  CIN 2                                    CIN stage 2 is a high-grade pre-cancerous lesion.
  CIN 3                                    CIN stage 3 is a high-grade pre-cancerous lesion.
  Localised cervical cancer (undetected)   Localised cervical cancer (undetected) is the early-stage cervical cancer state.
  Localised cervical cancer (detected)     Women with detected cancer (any stage) are not explicitly subject to disease progression or regression. Women with detected cancer (any stage) are subjected to a probability of cervical cancer mortality, increases with stage and which removes them from the model; alternatively, they may survive their disease.
  Regional cervical cancer (undetected)    Regional cervical cancer (undetected) is the mid-stage cervical cancer state.
  Regional cervical cancer (detected)      See localised cervical cancer (detected).
  Distant cervical cancer (undetected)     Distant cervical cancer (undetected) is the late-stage cervical cancer state (the cancer has metastasised and has low survival probability).
  Distant cervical cancer (detected)       See localised cervical cancer (detected).
  Cervical cancer survival                 Detected cervical cancer is in remission. Individuals in this compartment are no longer subject to cervical cancer mortality.

The model explicitly simulates the natural history of human papillomavirus infection for HPV types 16/18, HPV H5 and HPV OHR. The stage-, age- and HPV type-specific progression and regression rates are as published in previous analyses \[[@pone.0231388.ref039]\], and have been reproduced in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"}. HIV positivity status and viral suppression through ART both impact HPV acquisition and natural history; assumptions regarding the impact of HIV positivity on HPV natural history are summarised in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"}.

### Interventions {#sec011}

The model accounts for the impact of a range of HIV control interventions, including uptake of ART, PrEP, VMMC, and behavioural factors including the use of condoms. Effective use of ART in an individual infected with HIV not only acts to reduce disease progression and HIV-death but also significantly reduces the infectivity of virally suppressed patients. Further, use of PrEP, VMMC and condoms all lower the probability of disease acquisition to varying degrees. In the model, VMMC is specified by year, and we assumed rates were as reported in the literature and Tanzanian DHS reports \[[@pone.0231388.ref040]--[@pone.0231388.ref042]\]. The modelled VMMC rate applies to males of all ages, and reduces female to male HIV transmission by 60%, as consistent with the available evidence \[[@pone.0231388.ref043]\].

ART is also considered in two categories: those who are receiving ART, and those who are receiving ART and are 'virally suppressed'. The model assumes some mortality benefit for all individuals receiving ART, with viral suppression completely halting disease progression and/or HIV death, and reducing infectiousness by 96% \[[@pone.0231388.ref013]\]. The percentage of virally suppressed people living with HIV (PLHIV) in Tanzania was assumed to match figures published by UNAIDS \[[@pone.0231388.ref044]\].

Scenarios and outcomes {#sec012}
----------------------

A range of counterfactual and potential future HIV epidemic control scenarios were simulated, as described in [Table 4](#pone.0231388.t004){ref-type="table"}. For each scenario, we estimated cervical cancer incidence and cervical cancer mortality (stratified by HIV positivity) from 1995--2020, projecting these outcomes based on model hypotheses from 2020--2070. The absolute numbers of cervical cancer cases and deaths prevented by interventions to date (2020) are presented in this analysis, in addition to an age-standardised rate (ASR). The age-standardised rate is a weighted mean of the age-specific rates where weights (summing to unity) are derived from the 2015 estimated world female population \[[@pone.0231388.ref035]\], presented per 100,000 women.

10.1371/journal.pone.0231388.t004

###### Modelled scenarios of HIV control.

![](pone.0231388.t004){#pone.0231388.t004g}

  Scenario name and description                                                                  VMMC assumptions *υ*(*t*)[^1^](#t004fn001){ref-type="table-fn"}       ART assumptions[^2^](#t004fn002){ref-type="table-fn"}                                                                                                                                                            PrEP assumptions
  ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  **No interventions**. Exploratory worst-case counterfactual scenario.                          No VMMCs carried out.                                                 No ART uptake.                                                                                                                                                                                                   No PrEP available.
  **VMMC only**. Exploratory pessimistic counterfactual scenario.                                VMMC as historically observed, maintained at 80% from 2018 onwards.   No ART uptake.                                                                                                                                                                                                   No PrEP available.
  **VMMC and ART (baseline)**. Baseline scenario reflecting the current situation in Tanzania.   VMMC as historically observed, maintained at 80% from 2018 onwards.   Proportion of PLHIV receiving ART and virally suppressed as historically observed, and maintained at 47% from 2018 onwards.                                                                                      No PrEP available.
  **VMMC and target ART**. Exploratory optimistic scenario.                                      VMMC as historically observed, maintained at 80% from 2018 onwards.   Proportion of PL HIV receiving ART and virally suppressed as historically observed, and scaled up from 47% in 2018 to meet WHO '90-90-90' HIV control targets[^3^](#t004fn003){ref-type="table-fn"} from 2020.   No PrEP available.
  **VMMC, target ART and PrEP**. Exploratory best-case scenario.                                 VMMC as historically observed, maintained at 80% from 2018 onwards.   Proportion of PLHIV receiving ART and virally suppressed as historically observed, and is scaled up from 47% in 2018 to meet WHO '90-90-90' HIV control targets from 2020.                                       Daily PrEP use available to women engaging in commercial or transactional sex and their clients (90% uptake, 99% efficacy) from 2020.

^1^VMMC as historically observed assumes 8% VMMC until 1995, increasing to 23% in 1998, then increases quadratically to 80% in 2015, as observed \[[@pone.0231388.ref040], [@pone.0231388.ref042]\].

^2^ART as historically observed assumes introduction of ART in 2005, with a linear scale-up to 47% virally suppressed in 2017 \[[@pone.0231388.ref044]\].

^3^The 90-90-90 targets refer to the WHO global goal of achieving the following: 90% of all people living with HIV aware of their HIV status, 90% of all people diagnosed with HIV receive sustained ART, and 90% of all people receiving ART achieve viral suppression \[[@pone.0231388.ref045]\].

Sensitivity analysis {#sec013}
--------------------

A multivariate sensitivity analysis was carried out to assess the robustness of model outcomes to variation in a range of parameters. Parameters were selected for sensitivity analysis if they were either difficult to observe/report on, suspected to be highly influential, or directly affect the interventions assessed in the scenario analysis. The modelled effect of HIV control interventions is dependent on assumptions about the magnitude of their effectiveness, and, the literature indicates uncertainty surrounding the effect of VMMC, ART and PrEP \[[@pone.0231388.ref011], [@pone.0231388.ref016], [@pone.0231388.ref046]--[@pone.0231388.ref048]\]. Furthermore, any population or individual level behavioural change driven by implementation of these interventions is difficult to quantify, as perceptions of risk are constantly changing. However, evidence suggests that the availability and uptake of HIV control interventions may facilitate an increase in risky sexual practices to the order of up to 21% \[[@pone.0231388.ref049]--[@pone.0231388.ref054]\]. A Latin Hypercube Sampling (LHS) analysis over 6,000 possible parameter sets was utilised, the values of which are described in [Table 5](#pone.0231388.t005){ref-type="table"}.

10.1371/journal.pone.0231388.t005

###### Parameter variation considered in LHS analysis, and the rationale for selecting these parameters/ranges.

Parameters are described in S1 Table in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"}.
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  Parameter                                                                                                                                                                                                                                        Value ranges in sensitivity analysis                                                                                                                                                                                                                                                                                                                                                                                                                                              Rationale
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Intervention and behavioural parameters**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  **Sexual behaviour.** Per-timestep volume of sexual interactions possibly resulting in HIV transmission for high- and general activity males and females. The parameters varied were *c*~*M*~(*a*, *r*, *t*) and *c*~*F*~(*a*, *r*, *t*).        Parameters were varied by ±5% of the baseline value. The baseline values for these parameters are specified explicitly in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"}.                                                                                                                                                                                                                                                                                       This variation assessed the model's sensitivity to these parameters, while not producing excessive variation in simulation outcomes.
  **Condom usage.** Population-level behavioural change (i.e. disinhibition) resulting from uptake/availability of HIV control. The parameters varied were *k*~*HIV*~(*t*) and *k*~*HPV*~(*t*).                                                    Condom usage from 1990 to 2016 is reported in S1 Table in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"} and reflects observed usage in Tanzania, with the assumption that a condom was used in 37% of all high-risk interactions from 2016 onwards. In sensitivity analysis we considered variation in condom use from 2020 onwards, and the percentage of all high-risk interactions where a condom is used was varied uniformly over the interval 32--42%.   A range of studies reported that availability of HIV control interventions ART and PrEP can facilitate behavioural disinhibition where risk behaviours are increased in a population \[[@pone.0231388.ref049]--[@pone.0231388.ref054]\].
  **Mixing dimension.** Age-assortative mixing. The parameter varied was *λ*~*max*~.                                                                                                                                                               The maximum Poisson parameter *λ*~*max*~ was varied over a range *λ*~*max*~ = 1.5 (1.4, 1.6).                                                                                                                                                                                                                                                                                                                                                                                     Observed data indicates that males tend to mate with females younger than themselves \[[@pone.0231388.ref055]\].
  **VMMC efficacy (HIV).** Per sex-act reduction in HIV acquisition risk for circumcised males (compared to uncircumcised males). The parameter varied was *υ*~*HIV*~(*t*).                                                                        Relative risk reduction assumed in sensitivity analysis: 0.53--0.6 (0.6 assumed at baseline).                                                                                                                                                                                                                                                                                                                                                                                     Observed data indicates that circumcised men are 60% (53%-60%) less likely to acquire an HIV infection than uncircumcised men \[[@pone.0231388.ref046]\].
  **VMMC efficacy (HPV).** Per sex-act reduction in HPV acquisition risk for circumcised males (compared to uncircumcised males). The parameter varied was *υ*~*HPV*~(*t*).                                                                        Relative risk reduction assumed in sensitivity analysis: 0.16--0.85 (0.63 assumed at baseline).                                                                                                                                                                                                                                                                                                                                                                                   A pooled analysis reported that circumcised men are 37% (95% CI: 16%-85%) less likely to have an HPV infection than uncircumcised men \[[@pone.0231388.ref016]\].
  **HPV natural history on ART.** Impact of viral suppression through ART on HPV persistence and natural history among HIV infected women.                                                                                                         Baseline assumption: ART reduces additional risk of HPV/pre-cancer progression due to HIV positivity by 50%. Sensitivity analysis: ART reduces additional risk of HIV/pre-cancer progression by 0--100%.                                                                                                                                                                                                                                                                          A study, comparing relative risk of HPV acquisition among virally suppressed women to those not receiving ART, found that ART decreased HPV incidence (OR 0.64; 95% CI 0.46--0.88), but that this was not the case for high-risk HPV (OR 0.62; 95% CI 0.38--1.02) \[[@pone.0231388.ref047]\]. Another study found that women receiving ART are at lower LSIL risk (RR 0.67; 95% CI 0.45--1), and were 2.29 times more likely to regress from LSIL (95% CI 1.56--3.37) \[[@pone.0231388.ref011]\]. Overall, a systematic review and meta-analysis by Liu et al reported that the impact of ART on HPV-related disease is unclear \[[@pone.0231388.ref011]\].
  The specific values of multipliers specifying progression/regression of HPV related disease in HIV positive women compared to HIV negative women are outlined in S4 Table in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"}.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **PrEP efficacy.** Per sex-act reduction in HIV acquisition for daily PrEP users compared to non-PrEP users.                                                                                                                                     Baseline relative risk reduction: 0.99. Range assumed in sensitivity analysis: 0.92--0.99.                                                                                                                                                                                                                                                                                                                                                                                        The iPrEx study found that PrEP can reduce HIV risk by 92%-99% for daily use among HIV-negative individuals \[[@pone.0231388.ref048]\].
  **Underlying transmission and natural history parameters**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **HIV transmission.** Stage-specific per-contact probability of HIV transmission                                                                                                                                                                 Multipliers against the base HIV transmission probability: Multiplier for 'WHO clinical stage 2' (*p*~2~) = 4.3 (2.25, 17.91)                                                                                                                                                                                                                                                                                                                                                     Ranges are derived from confidence intervals given in Quinn et al. \[[@pone.0231388.ref056]\].
  Multiplier for 'WHO clinical stage 3' (*p*~3~) = 6.5 (2.93, 19.97)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Multiplier for 'WHO clinical stage 4' (*p*~4~) = 8.7 (5.28, 36.99)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **HIV acquisition (female-to-male ratio).** The relative risk of HIV acquisition per sexual contact for females compared to males. The parameter varied was *p*~*f*~, where $T_{MF}^{HIV{(Tx)}} = p_{f}T_{FM}^{HIV{(Tx)}}$.                      The multiplier *p*~*f*~ was found to be 2.5 through calibration and was varied between 2.2 and 2.8 in sensitivity analysis.                                                                                                                                                                                                                                                                                                                                                       Ranges were based on observed data published in Quinn et al. \[[@pone.0231388.ref056]\].
  **HPV transmission.** Type-specific HPV transmission probabilities per sex act.                                                                                                                                                                  $T_{FM}^{HPV_{1618}} = 0.056 - 0.078$                                                                                                                                                                                                                                                                                                                                                                                                                                             This variation assessed the model's sensitivity to these parameters, while not producing excessive variation in simulation outcomes.
  $T_{FM}^{HPV_{H5}} = 0.0134 - 0.0448$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  $T_{FM}^{HPV_{OHR}} = 0.0202 - 0.056$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Where $T_{FM}^{HPV} = T_{MF}^{HPV}$ for all HPV types.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **HIV-dependent HPV natural history.** HPV-type specific multipliers for acquisition, progression and regression of HPV associated disease for HIV positive individuals.                                                                         The ranges considered are as described in in S4 Table in [S1 File](#pone.0231388.s001){ref-type="supplementary-material"}.                                                                                                                                                                                                                                                                                                                                                        Ranges were based on data published in Liu et al 2018 \[[@pone.0231388.ref011]\].

Results {#sec014}
=======

Calibration and validation {#sec015}
--------------------------

Simulations from the calibrated model were consistent with observed HIV-specific outcomes including male and female HIV prevalence, total HIV incidence and number of HIV deaths ([Fig 3](#pone.0231388.g003){ref-type="fig"}), in addition to age-specific 2018 cervical cancer incidence and mortality rates ([Fig 4](#pone.0231388.g004){ref-type="fig"}).

![Calibrated HIV outcomes.\
(A) and (B) male and female HIV prevalence from 1995 to 2015; (C) HIV incidence from 1995 to 2015; (D) number of HIV deaths from 1995 to 2015. Error bars are 95% CI of observed data. Training data sourced from UNAIDS \[[@pone.0231388.ref022], [@pone.0231388.ref030],[@pone.0231388.ref031],[@pone.0231388.ref057]\].](pone.0231388.g003){#pone.0231388.g003}

![Calibrated (A) age-specific cervical cancer incidence and (B) mortality for the year 2018 compared to estimated data sourced from the International Agency for Research on Cancer IARC \[[@pone.0231388.ref023]\].](pone.0231388.g004){#pone.0231388.g004}

Following the model calibration procedure, where parameters were chosen such that the model was a good fit to UNAIDS and Globocan (IARC) data \[[@pone.0231388.ref022], [@pone.0231388.ref023], [@pone.0231388.ref030], [@pone.0231388.ref031]\], the model was validated against independent datasets. These included sex- and age-specific HIV prevalence ([Fig 5A and 5B](#pone.0231388.g005){ref-type="fig"}) and the sex-specific age distribution of AIDS diagnoses ([Fig 5C and 5D](#pone.0231388.g005){ref-type="fig"}), age-specific HPV prevalence ([Fig 6](#pone.0231388.g006){ref-type="fig"}), and the prevalence of HSIL (high-grade squamous intra-epithelial lesion; considered equivalent to a diagnosed CIN 2/3) among HIV negative versus positive women from the PROTECT study \[[@pone.0231388.ref058]\] ([Fig 7](#pone.0231388.g007){ref-type="fig"}).

![(A) and (B) Age-specific HIV prevalence for males and females in 2016 compared to observed data; (C) and (D: age-distribution of AIDS diagnoses for males and females in 2011 compared to observed data.\
Observed data from the Tanzanian Ministry of Finance (no confidence intervals available) \[[@pone.0231388.ref026], [@pone.0231388.ref059]\].](pone.0231388.g005){#pone.0231388.g005}

![(A), (B) and (C) Age-specific HPV prevalence in cervical cytology (all cytological results) of HPV 16/18, HPV H5 and HPV OHR compared to observed data.\
Observed data from Dartell et al 2012 (no confidence intervals available) \[[@pone.0231388.ref058]\].](pone.0231388.g006){#pone.0231388.g006}

![Age specific rates of HSIL (detected high-grade squamous intraepithelial lesion consistent with CIN2/3) prevalence for (A) HIV positive and (B) HIV negative women.\
Observed data from Dartell et al 2012 (no confidence intervals available) \[[@pone.0231388.ref058]\].](pone.0231388.g007){#pone.0231388.g007}

Scenario analysis {#sec016}
-----------------

The model estimates that there were 2,843 (and 1,039) fewer cervical cancer cases (and deaths), and 33,648 fewer total deaths (HIV and cervical cancer combined) from 1995 to 2020 as a result of the introduction and scale-up of VMMC. Assuming VMMC is maintained at 2018 levels, by 2070, VMMC is expected to have averted 330,400 (and 186,260) cervical cancer cases (and deaths) and save 3.47 million lives (HIV and cervical cancer combined) ([Table 6](#pone.0231388.t006){ref-type="table"}; [Fig 8B and 8D](#pone.0231388.g008){ref-type="fig"}). ART use to 2020 is estimated to have led to an additional 1,573 (and 1,222) cervical cancer cases (and deaths) from 1995--2020; this is due to ART reducing the competing risk of mortality due to HIV. The cumulative number of deaths averted by ART is predicted to reach 2,253,700 by 2070 and will have prevented 52,430 (and 16,390) additional cervical cancer cases (and deaths) by 2070 ([Table 6](#pone.0231388.t006){ref-type="table"}; [Fig 8B and 8D](#pone.0231388.g008){ref-type="fig"}).

![(A) Annual cervical cancer cases averted due to VMMC and ART (negative values under ART denote additional cases rather than cases averted); (B) cumulative cervical cancer cases averted due to VMMC and ART; (C) annual cervical cancer deaths averted due to VMMC and ART; (D) cumulative cervical cancer deaths averted due to VMMC and ART.](pone.0231388.g008){#pone.0231388.g008}

10.1371/journal.pone.0231388.t006

###### Number of prevented cervical cancer cases (and deaths) due to VMMC and ART.

Note that values presented reflect the incremental benefit of each intervention, and that negative values denote additional cases/deaths.

![](pone.0231388.t006){#pone.0231388.t006g}

                                                                                                 Prevented by VMMC   Prevented by ART
  ---------------------------------------------------------------------------------------------- ------------------- ------------------
  Cervical cancer cases (deaths) prevented cumulatively from 1995 to 2020                        2,843 (1,039)       -1,573 (-1,221)
  Deaths due to HIV or cervical cancer (total deaths) prevented cumulatively from 1995 to 2020   33,648              147,262
  Cervical cancer cases (deaths) prevented cumulatively from 1995 to 2070                        330,400 (186,260)   52,430 (16,390)
  Deaths due to HIV or cervical cancer prevented cumulatively from 1995 to 2070                  3,469,800           2,253,700

VMMC is predicted to substantially reduce both HPV and HIV prevalence in Tanzanian men and women ([Table 7](#pone.0231388.t007){ref-type="table"}, [Fig 9](#pone.0231388.g009){ref-type="fig"}). By 2070, VMMC is predicted to reduce HPV prevalence in men and women by 28% (44.71% under 'No interventions' to 32.13% under 'VMMC only' in 2070) and 17% (46.39% under 'No interventions' to 38.56% under 'VMMC only'), respectively. Similarly, the estimated reduction in HIV prevalence due to VMMC is 75% (7.59% under 'No interventions' to 1.86% under 'VMMC only') and 71% (8.47% under 'No interventions' to 2.46% under 'VMMC only'), respectively, for men and women. Compared to the 'No intervention' scenario, the introduction and scale-up of ART and PrEP is estimated to reduce HIV prevalence in men and women by approximately 99% (to 0.05% in males and 0.11% in females) in 2070.

![(A) and (B) Male and female HPV prevalence; (C) and (D) male and female HIV prevalence from 1995 to 2070 under five intervention scenarios.](pone.0231388.g009){#pone.0231388.g009}

10.1371/journal.pone.0231388.t007

###### Simulated HPV and HIV prevalence for males and females in 2070 (and 2020) under five scenarios.

Note that intervention start-year occurs pre-2020 for simulated interventions.

![](pone.0231388.t007){#pone.0231388.t007g}

                                  HPV prevalence in 2070 (2020 value)   HIV prevalence in 2070 (2020 value)                   
  ------------------------------- ------------------------------------- ------------------------------------- --------------- ---------------
  **No interventions**            44.71% (47.43%)                       46.39% (49.42%)                       7.59% (5.22%)   8.47% (6.07%)
  **VMMC only**                   32.13% (34.43%)                       38.56% (42.45%)                       1.86% (3.19%)   2.46% (4.89%)
  **VMMC and ART (baseline)**     31.90% (34.38%)                       38.28% (42.30%)                       0.41% (2.57%)   0.59% (4.24%)
  **VMMC and target ART**         31.85% (34.38%)                       38.22% (42.30%)                       0.12% (2.57%)   0.19% (4.24%)
  **VMMC, target ART and PrEP**   31.83% (34.38%)                       38.20% (42.30%)                       0.05% (2.57%)   0.11% (4.24%)

The introduction and scale-up of HIV preventions is expected to reduce the age-standardised rates of cervical cancer incidence and mortality over time. VMMC is expected to reduce cervical cancer incidence and mortality rates by 36--40% in 2070 compared to 2020 rates (under 'VMMC and ART (baseline)' scenario), whereas the provision and scale-up of ART to meet World Health Organisation 90-90-90 HIV control targets reduces cervical cancer incidence and mortality rates by 41--45% in 2070 compared to the current rates in 2020. Absolute rates of cervical cancer incidence and mortality are presented in [Table 8](#pone.0231388.t008){ref-type="table"} and visualised in [Fig 10](#pone.0231388.g010){ref-type="fig"}. Here, we note that the reductions in cervical cancer incidence and mortality due to ART among all women are driven by reductions among HIV positive women.

![(A) and (B) Age-standardised cervical cancer incidence and mortality rates among all women aged 0--99 years; (C) and (D) cervical cancer incidence and mortality rates among HIV negative women aged 0--99 years; (E) and (F) cervical cancer incidence and mortality rates among HIV positive women aged 0--99 years.\
Age-standardised rates are calculated using the 2015 World Female Population \[[@pone.0231388.ref035]\].](pone.0231388.g010){#pone.0231388.g010}

10.1371/journal.pone.0231388.t008

###### Simulated age-standardised cervical cancer incidence and mortality rates per 100,000 women, for all women (and stratified by HIV positivity) in 2070 (and 2020) under five scenarios.

Rates are standardised to the WFP2015 population. \[[@pone.0231388.ref035]\]

![](pone.0231388.t008){#pone.0231388.t008g}

                                  Age-standardised cervical cancer incidence rate per 100,000 women in 2070 (2020 value)   age-standardised cervical cancer mortality rate per 100,000 women in 2070 (2020 value)                                                     
  ------------------------------- ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------- --------------- --------------- -----------------
  **No interventions**            55.11 (64.39)                                                                            40.52 (44.69)                                                                            269.89 (291.46)   37.31 (41.99)   28.43 (29.70)   182.27 (198.01)
  **VMMC only**                   39.93 (63.00)                                                                            35.04 (42.99)                                                                            256.25 (286.92)   27.72 (41.47)   24.61 (28.91)   176.04 (197.85)
  **VMMC and ART (baseline)**     37.31 (65.42)                                                                            35.17 (42.99)                                                                            220.23 (288.57)   26.44 (43.27)   24.68 (28.88)   168.01 (204.14)
  **VMMC and target ART**         36.28 (65.42)                                                                            35.19 (42.99)                                                                            208.82 (288.57)   25.72 (43.27)   24.70 (28.88)   166.81 (204.14)
  **VMMC, target ART and PrEP**   35.82 (65.42)                                                                            35.20 (42.99)                                                                            192.90 (288.57)   25.35 (43.27)   24.71 (28.88)   158.74 (204.14)

Sensitivity analysis {#sec017}
--------------------

Findings from the multivariate sensitivity analysis indicate that the simulation outcomes are highly sensitive to variation in parameters specifying sexual behaviour, disease transmission and natural history, and, intervention effectiveness. [Fig 11](#pone.0231388.g011){ref-type="fig"} summarises the baseline and total variation in 2070 endpoint predictions for all simulated outcomes over the five scenarios.

![(A) and (B) Male and female HPV prevalence; (C) and (D) male and female HIV prevalence; (E) and (F) cervical cancer incidence and mortality among all women; (G) and (H) cervical cancer incidence and mortality among HIV negative women; (I) and (J) cervical cancer incidence and mortality among HIV positive women, simulated in the year 2070 (error bars correspond to the total variation generated by the sensitivity analysis).](pone.0231388.g011){#pone.0231388.g011}

An analysis of partial rank correlation coefficients indicate that cervical cancer incidence is most strongly correlated with VMMC efficacy for HPV prevention (correlation coefficient of -0.25; [Fig 12](#pone.0231388.g012){ref-type="fig"}), followed by VMMC efficacy for HIV prevention (correlation coefficient of -0.13).

![Correlation strength of selected outputs (HIV and HPV prevalence for males and females, and cervical cancer incidence and mortality) against intervention and behavioural parameters varied in multivariate sensitivity analysis.\
Partial rank correlation analysis was performed on the 'VMMC, target ART and PrEP' scenario, as it is the only scenario considering all modelled interventions.](pone.0231388.g012){#pone.0231388.g012}

Discussion {#sec018}
==========

To our knowledge, this analysis is the first to directly estimate the impact over time of changing VMMC prevalence, ART utilisation and PrEP uptake on cervical cancer in any setting. Findings from this analysis are likely to be broadly applicable to other low-income settings with high HIV prevalence and cervical cancer incidence rates, particularly in sub-Saharan Africa. These HIV control interventions were found to have a substantial impact on cervical cancer incidence and mortality in Tanzania. Using a simulation model of HIV and HPV transmission to estimate cervical cancer cases, cervical cancer deaths and total deaths (including HIV deaths) in Tanzania from 1995 to 2070 in the context of currently implemented HIV control measures, we estimated that VMMC has prevented 2,843 cervical cancer cases and 1,039 cervical cancer deaths from 1995 to 2020. Perhaps a less intuitive finding is that, while the addition and scale-up of ART in HIV-positive women reduces both overall HIV and HPV prevalence (women effectively treated with ART are less likely to acquire HPV and more likely to clear an HPV infection than their untreated counterparts), ART is estimated to have resulted in some 1,573 additional cervical cancer diagnoses and 1,221 additional cervical cancer deaths, cumulatively, from 1995 to 2020. These additional cases and deaths are among HIV infected women and are caused by the removal of HIV-related death as a competing risk, as some women who would have otherwise died from HIV-related causes will develop cervical cancer and subsequently die from it, in the absence of scaled-up cervical cancer prevention. In the longer-term, the protective effect of ART prevails, as scale-up to meet World Health Organisation 90-90-90 HIV control targets would result in cervical cancer incidence and mortality rates that are 43% (37.31 c.f. 65.42 cases per 100,000 women per year) and 39% (26.44 c.f. 43.27 deaths per 100,000 women per year) lower, respectively, in 2070 compared to the current rates in 2020.

The model prediction for HIV prevalence over time is consistent with empirical data for Tanzania \[[@pone.0231388.ref022], [@pone.0231388.ref030]\], and, future predictions are broadly consistent with the findings from HIV modelling studies specific to sub-saharan Africa \[[@pone.0231388.ref060]\]. A comparative modelling study utilising predictions from four independent models predicts that under a scenario assuming universal HIV testing and treatment (up to 90% coverage), HIV prevalance will be reduced to 0--3% in sub-Saharan Africa in 2050. The current analysis predicts that HIV prevalence in Tanzania in 2050 will be 0.12% in males, and 0.19% in females aged 15--49 years in the 'VMMC and target ART' scenario. In addition to this, predicted HPV prevalence in males (35.4% in 2017) under the 'VMMC and ART (baseline)' scenario showed relatively consistent agreement with observed HPV prevalence in South Africa in 2017 (40%) \[[@pone.0231388.ref061]\], and, predictions published by Tan et al \[[@pone.0231388.ref013]\]. Similarly, Tan et al predict that the cervical cancer incidence rates in KwaZulu Natal women will be approximately 31 cases per 100,000 among HIV negative women in 2070, and approximately 145 cases per 100,000 among HIV positive women ([S1 File](#pone.0231388.s001){ref-type="supplementary-material"}) \[[@pone.0231388.ref013]\]. For Tanzania, our analysis predicts 35.17 cases per 100,000 women among HIV negative women, and 220.23 cases per 100,000 among HIV positive women under the 'VMMC and ART (baseline)' scenario in 2070. In both analyses, the cervical cancer incidence rate in HIV positive women is close to five times higher than the rate among HIV negative women.

The dynamic and highly detailed nature of the model of HIV and HPV co-infection is a strength of this study. The model is stratified by sex, age, sexual activity level (including women engaging in transactional and commercial sex), HIV positivity (including disease stage and treatment status) and HPV positivity (including disease stage/detection status) for multiple HPV types; this allows exploration of disease transmission and progression dynamics in detail, accounting for herd protective effects and the protective effects of ART.

This analysis was limited by the inherent uncertainty surrounding input parameter assumptions, in particular, sexual behaviour assumptions including condom usage. In many settings which have implemented such HIV controls, a reduction in safe sex practices and an increase in other sexually transmitted infections is often observed \[[@pone.0231388.ref049]--[@pone.0231388.ref054]\]. A recent study into the sexual behaviour of PrEP users in Amsterdam found that daily PrEP use among HIV negative men who have sex with men (MSM) was associated with a 2--9% increase in condomless sex acts \[[@pone.0231388.ref050]\]; whereas another study has reported a 21% increase in risky sexual practice, and an increase in HIV incidence, among the San Franciscan MSM population since the advent of ART \[[@pone.0231388.ref053]\]. Sensitivity analysis findings indicate that HPV and HIV prevalence, and cervical cancer incidence and mortality are highly sensitive to variations in condom usage, therefore if condom usage trends over time vary, model predictions could substantially under-estimate or over-estimate disease burden. A number of simplifying assumptions were also made regarding the effect of ART on HPV natural history in HIV positive women; namely, we assume that ART affects all HPV types to the same degree, and, that commencing ART has the same effect on HPV natural history regardless of CD4+ count or HIV disease stage. Furthermore, the HIV transmission component of this model accounts for heterosexual transmission only, which is based on the assumption that the impact of HIV transmitted via sexual contact between men, and injection drug use, will have negligible impacts on the cervical cancer in women. Cervical cancer is an AIDS defining disease; therefore, there is a degree of uncertainty surrounding the true cervical cancer mortality rates in Tanzania, that is, whether a cervical cancer death in a HIV positive woman was attributed to cervical cancer or HIV \[[@pone.0231388.ref062]\]. The grouping of many individual HPV genotypes in the model, for example HPV 16/19, HPV 31/33/45/52/58 (HPV H5) and a category for "other high-risk HPV types", may impact the overall simulated HPV prevalence in addition to the overall transmission dynamics of the model; for example, in this model it is impossible to discern whether individuals are infected with only one or any combination of the HPV genotypes in each simulated HPV subgroup. This may result in an overestimation of effectiveness of interventions targeted at HPV reduction. Finally, the findings of this study must be interpreted in the context of the lengthening life expectency in Tanzania, which is explicitely accounted for in this analysis. Due to reductions in HIV mortality in addition to other cause mortality (e.g. driven by improvements in sanitation and health care), the life expectancy at birth is expected to rise to 75 years in 2065--2070 (compared to 54 years in 1995--2000) \[[@pone.0231388.ref034]\]. This will necessarily result in an increased opportunity for the development of cervical cancer (and other diseases), irrespective of additional effects due to HIV treatment.

In 2019, a draft global strategy for the elimination of cervical cancer as a public health problem was released by the World Health Organisation \[[@pone.0231388.ref063]\]. This strategy, to be considered by the World Health Assembly in May 2020, defines that cervical cancer is eliminated as a public health problem when all countries achieve an incidence rate of less than four cases per 100 000 women per year. To achieve this target, the WHO recommends that each country implement HPV vaccination programmes whereby 90% of girls are vaccinated by the age of 15, organised cervical screening programmes whereby 70% of women are screened at least twice per lifetime, and effective management of 90% of women diagnosed with cervical pre-cancer or invasive cervical cancer \[[@pone.0231388.ref063]\]. While VMMC and ART can reduce the burden of cervical cancer in Tanzania in the long term, they are not sufficient to bring cervical cancer incidence beneath the threshold proposed by the WHO for cervical cancer elimination. Our finding that even under the best-case scenario the rate of cervical cancer incidence in all Tanzanian women is not reduced below 35 cases per 100,000 women per year (more than eight fold higher than the elimination threshold) demonstrates the importance and urgency of scaling up cervical cancer prevention programs, such as HPV vaccination and cervical screening, as well as HIV control, in order to avoid the situation that lives saved from HIV-related death are instead lost to cervical cancer. The WHO call for global action to eliminate cervical cancer as a public health problem is an important opportunity to galvanise and unite efforts to prevent cervical cancer in Tanzania and globally \[[@pone.0231388.ref064]\].
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Additional Editor Comments:

Dear Authors,

two expert referees suggested major revisions and a third referee suggested minor but extensive changes.

As a consequence of the report and of my personal assessment of your manuscript, your manuscript needs a \"major revision\".

Please implement and reply all suggestions and questions of the three referees.

Regards,

Alberto d\'Onofrio

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors present a modeling study on the effect of HIV treatment and control interventions on HPV morbidity and mortality in Tanzania over the period 1995-2070. They estimate relative reductions in HPV-related cervical cancers, cancer deaths, and overall (HIV+HPV-related) deaths, avoided via the rapid adoption of medical male circumcision observed in the country (from 8% in 1995 to 80% in 2015) and by the current and future scale-up of antiretroviral therapies and PrEP. Interstingly, they found that ART therapies may temporally increase the incidence of cervical cancer and associated mortality by increasing the life expectancy of HIV+ women who are therefore exposed for a much longer time to the risk of acquiring HPV-related cervical cancer.

The paper is well thought out, the model is carefully parameterized and thoroughly validated, and the sensitivity analysis seems sufficient to grant the robustness of results. I have only a few minor comments:

\* Figure 1 needs some revision:

\- the zero lines for the left and right y-axes in Fig1A are not aligned;

\- the y range in Fig1A touches the axis, it would be better to leave some blank space below bars to avoid the doubt that the plot is clipped;

\- I think that colors are inverted for VMMC and ART in Fig1A and 1B;

\- the use of a double axis is not really necessary: I would recommend splitting each panel in two separate panels;

\* showing percent reductions computed on percentages can be misleading; for example, when at line 141 the authors mention a reduction of 27.58% and 14.35% on HPV prevalence in men and women, they mean that the HPV prevalences reduces from 50% to \~36% and from 55% to \~47%; but it could be misinterpreted as a reduction from 50% to 50-27.58 = 22.62% and 55-14.35= 40.65%. To avoid possible misunderstandings, I recommend to declare final prevalences, (possibly indicating relative reductions with expressions such as \"by approximately one fourth / one seventh\").

\* age-group limits vary by type of estimate: 20-64 years old for HPV prevalence, 15-49 for HIV prevalence, 0-80 for cervical cancer incidence. I believe this was done to comply with parametrization/calibration data: if so, can the authors state it explicitly? In addition, it could be useful to provide age-specific prevalence/incidence predicted by the model at different time points to give a better idea on which age groups are most impacted by interventions;

\* the reduction on condom usage observed between 2011 (58%) and 2016 (37%) is remarkable and worrying. Considering that the trend had been consistently increasing in the previous years, can the author comment on this sudden drop? Could it be related to a measurement error/spurious data? It would be interesting to explore a scenario where the condom usage levels are reverted to at least the 2011 levels, e.g. through awareness campaigns;

\* ASR (age-standardized rate?) is undefined in y labels of Fig4-6; in Fig the y lab of Fig6, a closed parenthesis is missing;

\* the description of results could be improved by reducing the text commenting figures and collecting the reported values in a table comparing scenario results for different target variables. For example, for Fig. 2 and 5, I would not spend too much text in commenting a substantially equivalent prediction for all intervention scenarios (differences in scenario results are likely to be non-significant with respect to uncertainties in parameter values). Similar simplifications can be done for other Figures, allowing the reader to focus his/her attention on really different dynamics and mechanisms underlying them;

\* at line 335, the authors mention an elimination threshold proposed by the WHO for cervical cancer: how much is it? Considering that HPV vaccination is already implemented in the code, why don\'t the authors use it to provide scenarios at different coverage levels, in such a way to suggest possible targets for a vaccination campaign aimed at elimination?

\* I expect the increase in life expectancy projected for Africa in the next decades to have a very dramatic effect on chronic infections such as HPV and HIV, contributing with a similar mechanism as ART (the reduction of competing mortality) to the rise of cervical cancers and possibly HIV prevalence. If the authors can\'t include projected mortality rates in the model, they should discuss this as a model limitation and qualitatively speculate on the likely impact of this issue.

Reviewer \#2: The paper is an interesting one because it sets-up a relevant issue namely, which are the implications that successful control measures against HIV in Sub- Saharan Africa (SSA) might have for other ST infections representing an important public health burden, first of all HPV.

However, the manuscript should be improved in a number of directions, departing from the introduction.

First, the description of the context of HIV-HPV in Tanzania is somewhat scanty. For example, it is mentioned at L63 that incidence of CC in Tanzania was among the highest in the world, are there explanations for such a high incidence rate of CC in Tanzania? This cannot simply be HIV- and underlying causes, which is the leit-motiv of the manuscript, given that the Tanzanian HIV epidemic is very far from being among the worst HIV epidemic in SSA.

Also, some lines framing the state of HIV & HPV in Tanzania within the broader framework of such diseases in Sub-Saharan Africa as a whole would be very welcome by potential readers.

Parallel to this also the state and perspective of current interventions against HIV in Tanzania should be introduced. I am surprised authors do not consider condom use at all, which is still dramatically suboptimal in SSA. Similarly, nothing is said about interventions against HPV, particularly about the access to vaccination (unless this is in the Sup Mat).

L32 (and related sentences in the Results) The remark on the enhancing effect that ART will have on CC is not surprising from a demographic viewpoint: in the history of mankind any control reducing the impact of a deadly infective cause will unavoidably open room for other mortality causes.

L68. (and related sentences in the Results) This sentence is somewhat ambiguous: it is not clear whether the paper also aims to represent a model of the impact of HIV intervention on HIV itself. According to what stated here the answer seems to be \"no\", that is the role of modelling HIV seems to be purely "of service" for modelling its output on HPV. Is this correct? I understand that the model of HIV is quite oversimplified which does not make it a good model for predicting the HIV epidemics per se, but in this case one should perhaps motivate why then to model HIV at all, rather than, simply taking the most parsimonious choice namely, postulating some direct effects that HIV control measures in place in Tanzania might have for HPV circulation and eventually for progression to CC. This point should be considered carefully.

Model presentation is very rapid, with all details relegated to the Sup Mat. However, readers would like to have the possibility to judge about the goodness of the adopted model (it is by this goodness that we can judge the relevance of the model predictions) without the need to continuously switch to the Sup Mat. Therefore, I recommend that the part of the results that deal with the estimation of critical model parameters (basically, the "Calibration results" of Sup Mat 1) are reported in the main text in the Results section. Yet, the Sup Mat 1 should be better organised. There are no model equations, the demographic part is a bit unclear (seemingly the authors use a variable population, but this is totally contrasting with the idea that the population is "uniformly distributed over 5-years age groups" etc), information on mixing patterns and related references should be made clear and usable by readers.

Specific points

L17 "59.1 per 100,000" per year

L18 \"the impact that intervention aimed at controlling HIV\"

L21 It is not made clear to readers that these are the three main interventions against HIV currently in place in Tanzania.

L26 It is unclear to what the figure of 24,967 total deaths actually refers to. From the results it appears that it is the sum of prevented deaths by AIDS and CC. This should be clarified.

L54 \"reduce HIV-1 acquisition\"? presume you mean \"hazard of acquisition\" but still is unclear, which unit are you referring to ? per single sexual act ? or what else ?

L56 prevelance

L64: (19) and (20) are independent studies so cit 19 should be reported after \"with HIV\"

Description "dual HIV-HPV" is often used. I suggest to use some cleared description.

L98 "For each scenario, we estimated HPV and HIV prevalence". At least over 2020-2070 you should say "we projected" (based on the model hypotheses)

I suggest to put Table 1 in concise form avoiding long verbal descriptions (that can be put in the caption) in table entries.

Reviewer \#3: The authors of this paper developed a deterministic transmission-dynamic model of HPV and HIV transmission, and natural history of HPV-related cervical cancer and HIV, to estimate the impact of actual and scaled-up HIV control actions on past and future trends of cervical cancer incidence and mortality in Tanzania. HIV control actions include voluntary medical male circumcision (VMMC), anti-retroviral therapy (ART), and pre-exposure prophylaxis. The model parameters were fixed based on the literature or calibrated to empirical data. Five scenarios of HIV control actions (no control, only VMMC, actual control with VMMC and ART, and three scaled-up control scenarios) were elaborated and compared in terms of cervical cancer incidence and mortality between 1995 and 2070. Age-standardized incidence of cervical cancer and mortality due to cervical cancer, number of deaths due to cervical cancers, number of cases of cervical cancer, and total number of death averted, HPV prevalence, HIV prevalence, were used as outcomes for comparison.

This study shows that interventions aimed at HIV prevention can have major indirect effect on cervical cancer. This important effect would be missed in a typical effectiveness analysis which does not include HPV infection and transmission. The authors' usage of a model of HPV/HIV transmission and development of subsequent cervical cancer is necessary if HIV infection can affect both HPV transmission and HPV natural history of disease. The mathematical model used appears adequate overall with a potential limitation regarding the grouping of HPV-genotypes (e.g., a single group for all cross-protective types). However, the calibration does not account sufficiently for the substantial parameter uncertainty related to the complicated and still uncertain interaction between HIV and HPV, and such uncertainty is not visible in the results presented. Hence, the present study requires some methodological adjustment but is a potentially important contribution to the assessment of HIV prevention effectiveness in Tanzania and other sub-Saharan countries of similar context.

Major comments

The estimation of the effect of parameters uncertainty on the results is unclear or inadequate in this study. To my understanding, two sensitivity analyses were done. In the first analysis, a subset of the parameters is varied and their impact on calibration targets is assessed: this cannot be used to estimate parameters uncertainty on the study outcomes (HIV control actions effectiveness). Even if varying a parameter does not have an impact on calibration target this does not mean that the parameter does not have an impact on effectiveness. For example, different combinations of parameter can lead to the same fit of pre intervention incidence, but produce sharp differences in post intervention effectiveness. In the second analysis, parameters related to the effect of HIV control actions (e.g., effect of circumcision on transmission) are varied and their impact on the study outcomes are ascertained, but this analysis does not include other uncertain parameters such as those related to sexual behavior. In the presentation of results, a single number is given with no uncertainty interval. It is highly unlikely that the numbers given are precise enough to justify omitting an uncertainty interval.

The methodology of this modelling study is complex and is difficult to explain thoroughly in a short article. However, some essential information is missing and was moved to the supplementary materials: 1) information on calibration methods, 2) calibration data related to sexual behavior. Overall, although a lot of information on the methods are in Appendices, there should still be sufficient information in the core paper for readers to understand the approach and key simplifying assumptions.

To help understand the results, they should include the overall impact of HIV interventions partitioned as the effect due to HIV reduction only plus the secondary effect on cervical cancer. This should be done with absolute and relative measures (number of deaths and mortality rates). Presenting only the absolute number of deaths averted is insufficient. Absolute numbers can be diluted by other effects such as population growth. Presenting both relative and absolute effects allow both to understand the underlying results (relative impact) and provide numbers for policy makers (absolute). In addition, relative numbers may help with generalizability (or discussion of generalizability) of the results to other settings.

The limits related to grouping HPV-genotypes should be at the minimum mentioned. Grouping HPV-types is known to produce "super-bug" in the general population. In the context of this study with an important HIV-infected population, it is not immediately clear what would be the impact of grouping genotypes. Given that people living with HIV have a high prevalence of HPV co-infections, grouping types may have an impact on results as individuals in the model cannot be co-infected by more than 3 super types (what happens with competing risks towards HPV-related disease, transmission dynamics, etc?).

I think more explanation of the following conclusions is needed: "These results demonstrate that HIV control measures will have a substantial effect in reducing HIV-related death in Tanzania, but will have an unintended consequence of increasing cervical cancer incidence and mortality in HIV-positive women for the next few decades, as a result of their increased life expectancy." "These findings demonstrate the importance and urgency of scaling up cervical cancer prevention programs, such as HPV vaccination and cervical screening, as well as HIV control, in order to avoid the situation that lives saved from HIV-related death are instead lost to cervical cancer."

In the results, the age-standardized mortality due to cervical cancer decreases after HIV prevention. Hence, it could be argued that HIV prevention has a positive effect on mortality rates due to cervical cancer. The increase is in absolute number of deaths due to cervical cancer, because deaths have been prevented and people are living longer. It would be good to have more discussion on this, so that readers better understand the implications. If childhood mortality is prevented, there will be more deaths among adults. If deaths are prevented among young adults, more deaths will occur among older adults, etc. Lives saved from HIV will results in substantial life years gained, which should not be mistakenly interpreted as something negative. Rather that it will have consequences on the number of cervical cancer cases, and thus provide even more justification for cervical cancer prevention. But not only for cervical cancer prevention as it will increase the number of deaths due to other prevalent diseases among people living with HIV.

 

Minor comments

In the No intervention scenario, condom usage declines between 2011 and 2016. However, could this be partially due to the HIV prevention measures? The authors mention that HIV prevention can affect sexual behavior and condom usage. If so, shouldn't the decline in condom usage be ignored in the No intervention scenario?

In First Supplementary Appendix to the article:

P. 3, last paragraph: \"The number of high-risk sexual interactions is defined as the total number of sexual interactions which could potentially result in HIV transmission.\" This sentence needs to be re-written, unless the assumption is that low-risk sexual interaction can't result in HIV transmission.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Giorgio Guzzetta

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

15 Jan 2020

Note that I have uploaded a \"Response to Reviewers\" document that is easier to follow.

Dear Dr d\'Onofrio,

Thank you for considering our manuscript titled The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: a modelling study. We would like to thank the reviewers and yourself for the comments, which we have endeavoured to incorporate.

Please note that the methods section of this manuscript has been almost entirely re-written to improve on the level of detail and clarity, as requested by yourself and the reviewers. The results section has also been substantially changed to include additional information about model calibration/validation outcomes. While we have endeavoured to eliminate/reduce the size of the supplementary appendix, it is still necessary to have one due to the large number of equations and sizable data tables.

It has been necessary to re-run the model with altered input assumptions in response to review comments. Namely, we have re-run the model to incorporate the projected future life-expectancy in Tanzania (correcting for improvements due to lowered HIV and cervical cancer mortality) and we have combined the two separate sensitivity analyses into one larger sensitivity analysis. Furthermore, we have edited the base population structure used for the age-standardisation in the presentation of cervical cancer incidence and mortality rates; this was done for consistency with recent literature published in the field of HPV/cervical cancer modelling (Simms et al 2019 <https://doi.org/10.1016/S1470-2045>(18)30836-2).

Please see our response to all comments in the below.

Best regards,

Michaela Hall on behalf of all co-authors

Comments from the editor

A\) Abstract: in the abstract you wrote \"A dynamic model of HIV and HPV infection and natural history was used to simulate \". This sentence is highly uninformative since there are a huge number of possible \"dynamic model \" based approaches. Please, in the revised ms you must clearly specify which class of models you used. You know, PLoS ONE is also read by people who are not scared by mathematics and statistics\...

For clarity, the methods section of the abstract (p2 line 22) has been edited to read "A deterministic transmission-dynamic compartment model".

B\) on line 75 you wrote that you used a \"deterministic Markov model" without mentioning any reference on this class of models. Unless you referred to \"piecewise deterministic Markov models\" (i.e. you made a misprint), the class of \"purely\" deterministic Markov models is very rare (and at the best of my knowledge of non-unique definition\...) and needs much more information for the readers of your manuscript. I am quite expert in many kinds of deterministic and stochastic modelling, and not only in the field of infectious diseases, but I very seldom read papers on this topic. Thus, please be very detailed and include references on these purely \"deterministic Markov models\". References that must be both in the field of mathematics and physics and in the field of applications concerning purely \"deterministic Markov models". For me they mean \"time discrete dynamical systems with some initial conditions and possibly parameters that are random variables\", but maybe my definition does not fully coincide with yours.

Thank you for pointing this out. The line now reads (for clarity and consistency with the abstract) "A deterministic transmission-dynamic compartment model". This can be found on line 90 (page 5).

C\) Linked to both point (B) and point (F) I feel that you model must be better described (even in the main text) from the mathematical and physical viewpoint, be very clear in specifying what is deterministic and what is stochastic

Please note that the methods section of the model has been substantially re-written to address editor and reviewer concerns over the level of detail provided. In order to more thoroughly (and clearly) describe the model, a new Table 1 has been inserted (p7 line 111). This table specifies that model compartments can be described as the cartesian product over nine vectors, labelled in the table as (A) through to (I) every compartment, and notes that all state transitions are deterministic. Note that the description for each process simulated by the model (e.g. births, deaths, ageing, infection, etc.) has been moved from the supplementary appendix to the main text.

D\) Please rewrite the section (1st suppl materials) \"Sexual behaviour and force of infection\" which in my opinion is not understandable and include it in the main text

As requested, this section has been entirely re-written for clarity, and relocated to the main text (see lines 146 to 195 over pages 10 to 12). The force of infection is now described using equations, for a mathematically inclined readership (see response to reviewer 2). Note that input parameter assumptions regarding calculation of the force of infection remain in the supplementary appendix due to it being a very large table spanning multiple pages.

E\) The above\--mentioned section \"Sexual behavior and force of infection\" shows that your model included important behavioral changes. It is a pity that the bibliography of your work does not include works in behavioural epidemiology of infectious diseases.

Available evidence suggests that the advent of effective HIV treatments (ART) and preventions (PrEP) have facilitated the observed (and modelled) behavioural disinhibition. This evidence has been discussed and referenced in the discussion on line 431, page 31.

"This analysis was limited by the inherent uncertainty surrounding input parameter assumptions, in particular, sexual behaviour assumptions including condom usage. In many settings which have implemented such HIV controls, a reduction in safe sex practices and an increase in other sexually transmitted infections is often observed(49-54). A recent study into the sexual behaviour of PrEP users in Amsterdam found that daily PrEP use among HIV negative men who have sex with men (MSM) was associated with a 2-9% increase in condomless sex acts(50); whereas another study has reported a 21% increase in risky sexual practice, and an increase in HIV incidence, among the San Franciscan MSM population since the advent of ART(53). Sensitivity analysis findings indicate that HPV and HIV prevalence, and cervical cancer incidence and mortality are highly sensitive to variations in condom usage, therefore if condom usage trends over time vary, model predictions could substantially under-estimate or over-estimate disease burden."

F\) materials to be included in the supplementary materials: I fully agree with the observation made by one of the referees: there is too much methodological material in the supplementary materials. 40 page of supplements are pathological for a manuscript of 42 pages. Moreover, many very important points are in the two supplements: they need to be transferred in the main body text. PLoS ONE is a purely online journal, so without space limitations. Thus I warmly invite the authors to add as much methodological material as possible in the full body of the manuscript. Moreover, if you feel that some material has to stay in supplemental materials, please provide a single supplementary materials file: it is more practical for reader to download a unique file than two or more.

We thank the editor and reviewers for this feedback and have taken this opportunity to move substantial portions of the supplementary appendices to the main text (see responses above). In addition, the supplementary material has been combined into a single file. Note that there still exists a supplementary appendix, which is now reserved for very large tables equations only.

Reviewer \#1: The authors present a modeling study on the effect of HIV treatment and control interventions on HPV morbidity and mortality in Tanzania over the period 1995-2070. They estimate relative reductions in HPV-related cervical cancers, cancer deaths, and overall (HIV+HPV-related) deaths, avoided via the rapid adoption of medical male circumcision observed in the country (from 8% in 1995 to 80% in 2015) and by the current and future scale-up of antiretroviral therapies and PrEP. Interestingly, they found that ART therapies may temporally increase the incidence of cervical cancer and associated mortality by increasing the life expectancy of HIV+ women who are therefore exposed for a much longer time to the risk of acquiring HPV-related cervical cancer.

The paper is well thought out, the model is carefully parameterized and thoroughly validated, and the sensitivity analysis seems sufficient to grant the robustness of results. I have only a few minor comments:

\* Figure 1 needs some revision:

\- the zero lines for the left and right y-axes in Fig1A are not aligned;

\- the y range in Fig1A touches the axis, it would be better to leave some blank space below bars to avoid the doubt that the plot is clipped;

\- I think that colors are inverted for VMMC and ART in Fig1A and 1B;

\- the use of a double axis is not really necessary: I would recommend splitting each panel in two separate panels;

Thank you for pointing out these issues and providing advice on increasing the readability of this figure. We have made the recommended changes to figure 1, which is now called "Figure 8".

\* showing percent reductions computed on percentages can be misleading; for example, when at line 141 the authors mention a reduction of 27.58% and 14.35% on HPV prevalence in men and women, they mean that the HPV prevalences reduces from 50% to \~36% and from 55% to \~47%; but it could be misinterpreted as a reduction from 50% to 50-27.58 = 22.62% and 55-14.35= 40.65%. To avoid possible misunderstandings, I recommend to declare final prevalences, (possibly indicating relative reductions with expressions such as \"by approximately one fourth / one seventh\").

Thank you for pointing this out. We have now included tables in the results section which report on the absolute values of model outcomes (including HIV/HPV prevalence's). This was to increase readability/clarity (as per your point here) and reduce the quantity of text in the results write-up (as per your point below). In particular, the prevalence of HIV and HPV are now explicitly reported in Table 7 (page 26, line 341).

\* age-group limits vary by type of estimate: 20-64 years old for HPV prevalence, 15-49 for HIV prevalence, 0-80 for cervical cancer incidence. I believe this was done to comply with parametrization/calibration data: if so, can the authors state it explicitly?

This is correct, the difference in age group limits for HIV prevalence, HPV prevalence and cervical cancer incidence was driven by what was reported in the available observed data (i.e. we utilised data in the age-groups reported by various sources). We have now stated this explicitly on page 9 (lines 120-122). "Note that different groupings in the age-range of calibration/validation results are due to variation in reported age-ranges in the observed data."

In addition, it could be useful to provide age-specific prevalence/incidence predicted by the model at different time points to give a better idea on which age groups are most impacted by interventions;

While it may be of some interest to provide age-specific breakdowns at various timepoints for all interventions, we are of the opinion that it is beyond the scope of the intended work (i.e. to estimate the impact of HIV prevention on cervical cancer over a long period of time). However, the model is calibrated to age-specific data, as presented in the results.

\* the reduction on condom usage observed between 2011 (58%) and 2016 (37%) is remarkable and worrying. Considering that the trend had been consistently increasing in the previous years, can the author comment on this sudden drop? Could it be related to a measurement error/spurious data? It would be interesting to explore a scenario where the condom usage levels are reverted to at least the 2011 levels, e.g. through awareness campaigns;

The sudden drop in condom usage over time is consistent with available evidence suggesting that the introduction of effective treatment (ART) promotes a level of behavioural disinhibition. For a more detailed response to this point, please see our reply above to the editor's point (E). Note that variation in condom usage over time is also considered in the sensitivity analysis.

\* ASR (age-standardized rate?) is undefined in y labels of Fig4-6; in Fig the y lab of Fig6, a closed parenthesis is missing;

Thank you pointing out this omission. The age-standardised rate has now been defined in all relevant figures. In addition, the calculation for the ASR is described on page 16-17 (lines 255 to 258). "Here, the age-standardised rate is a weighted mean of the age-specific rates where weights (summing to one) are derived from the estimated world female population aged 0-99 years (38), and is presented per 100,000 women."

\* the description of results could be improved by reducing the text commenting figures and collecting the reported values in a table comparing scenario results for different target variables. For example, for Fig. 2 and 5, I would not spend too much text in commenting a substantially equivalent prediction for all intervention scenarios (differences in scenario results are likely to be non-significant with respect to uncertainties in parameter values). Similar simplifications can be done for other Figures, allowing the reader to focus his/her attention on really different dynamics and mechanisms underlying them;

Thank you for this suggestion; we have now included data tables (table 6 on page 25, table 7 on page 26 and table 8 on pages 27-28) to summarise the model outputs and substantially reduce text.

\* at line 335, the authors mention an elimination threshold proposed by the WHO for cervical cancer: how much is it? Considering that HPV vaccination is already implemented in the code, why don\'t the authors use it to provide scenarios at different coverage levels, in such a way to suggest possible targets for a vaccination campaign aimed at elimination?

The World Health Organisation has released a draft strategy which proposes that cervical cancer could be considered eliminated as a public health problem in a country if the age-standardised rates of cervical cancer falls below 4 cases per 100,000 women, high coverage of human papillomavirus (HPV) vaccination, cervical screening and treatment of precancer, treatment of invasive cancer, and palliative care is implemented. This has now been clarified in the discussion section of the manuscript (lines 462-470 p32-33):

"In 2019, a draft global strategy for the elimination of cervical cancer as a public health problem was released by the World Health Organisation(63). This strategy, due to be assessed by the World Health Assembly in May 2020, defines that cervical cancer is eliminated as a public health problem when all countries achieve an incidence rate of less than four cases per 100 000 women per year. To achieve this target, the WHO recommends that each country implement HPV vaccination programmes whereby 90% of girls are vaccinated by the age of 15, organised cervical screening programmes whereby 70% of women are screened at least twice per lifetime, and effective management of 90% of women diagnosed with invasive cervical cancer(63)."

Addressing HPV vaccination strategies to eliminate cervical cancer in Tanzania is outside the scope of this particular paper (which addresses the unintended impacts of HIV) and will be the focus of a separate piece of work.

\* I expect the increase in life expectancy projected for Africa in the next decades to have a very dramatic effect on chronic infections such as HPV and HIV, contributing with a similar mechanism as ART (the reduction of competing mortality) to the rise of cervical cancers and possibly HIV prevalence. If the authors can\'t include projected mortality rates in the model, they should discuss this as a model limitation and qualitatively speculate on the likely impact of this issue.

We are pleased to say that we have re-run the model incorporate the projected age-specific annual mortality rates for Tanzania. Therefore, our model accounts for increasing life expectancy in general (and not just due to decreasing HIV death and cervical cancer mortality). We have clarified this point in lines 139-140 (p10) "Age-and-year-specific natural mortality rates specified using the projected year-on-year life tables reported by the United Nations Population Division(31)".

Reviewer \#2: The paper is an interesting one because it sets-up a relevant issue namely, which are the implications that successful control measures against HIV in Sub- Saharan Africa (SSA) might have for other ST infections representing an important public health burden, first of all HPV.

However, the manuscript should be improved in a number of directions, departing from the introduction.

First, the description of the context of HIV-HPV in Tanzania is somewhat scanty. For example, it is mentioned at L63 that incidence of CC in Tanzania was among the highest in the world, are there explanations for such a high incidence rate of CC in Tanzania? This cannot simply be HIV- and underlying causes, which is the leit-motiv of the manuscript, given that the Tanzanian HIV epidemic is very far from being among the worst HIV epidemic in SSA.

Thank-you. While HIV positivity does increase the likelihood that an HPV infection will progress to cervical cancer, it is not accurate to say that a high prevalence of HIV will necessarily result in high incidence of cervical cancer. Human papillomavirus infection is the causative agent of cervical cancer, but in addition to HPV exposure (and the prevalence of various HPV sub-types, which differs by geographic region),cervical cancer incidence depends on exposure to the known co-factors in HPV progression (multiparity, smoking, age at first full term pregnancy, and use of oral contraceptives, as well as HIV) and also whether or not any level of opportunistic cervical screening is done. Also note that there are major limitations in the availability of IARC certified registry data in SSA so caution should be used in comparisons between countries.

Also, some lines framing the state of HIV & HPV in Tanzania within the broader framework of such diseases in Sub-Saharan Africa as a whole would be very welcome by potential readers.

Parallel to this also the state and perspective of current interventions against HIV in Tanzania should be introduced. I am surprised authors do not consider condom use at all, which is still dramatically suboptimal in SSA. Similarly, nothing is said about interventions against HPV, particularly about the access to vaccination (unless this is in the Sup Mat).

We thank the reviewer for their suggestion. Please note that condom usage is considered and explicitly modelled in this analysis, please refer to Table s1 in the supplementary appendix. Some additional framing context on HPV and HIV in Tanzania and sub-Saharan Africa has been included in the introduction. See lines 66-83 on pages 4-5 which now read:

"The United Republic of Tanzania has a high burden of both HIV and cervical cancer. It is estimated that in 2018, 5.5% of Tanzanian women aged 15-49 years were living with HIV(22), while the incidence of cervical cancer was among the highest globally, at 59.1 cases diagnosed per 100,000 women (9,771 cervical cancers detected) in 2018(23). The 2018 incidence rates of cervical cancer in Southern Africa and Eastern Africa were 43.1 cases per 100,000 women per year, and 40.1 cases per 100,000 women per year, respectively(23). Tanzania is within the sub-Saharan African region, which in 2018 contained 53% of all people living with HIV globally and had an estimated HIV prevalence among adults aged 15-49 years of 7%(24, 25). The two main interventions against HIV currently in place in Tanzania are ART for HIV positive individuals, and VMMC, which are both being actively scaled up(26); while the Tanzanian Ministry of Health recommends PrEP use for those at significant risk of HIV acquisition, scale up of access to PrEP has been minimal(27). In light of Tanzania's high burden of cervical cancer and the known impact of HIV, it is important to assess the impact of HIV control interventions that are currently being scaled up (ART and VMMC) or considered (PrEP) on not only HIV incidence and prevalence, but also rates of cervical cancer incidence and mortality. While there exists significant variation in national laws pertaining to sexual identity and orientation, sex-work and access to contraception across the African continent which affects local rates of sexually transmitted diseases(24), the relative impact of HIV interventions on cervical cancer incidence rates in Tanzania is likely to be broadly representative of the region."

L32 (and related sentences in the Results) The remark on the enhancing effect that ART will have on CC is not surprising from a demographic viewpoint: in the history of mankind any control reducing the impact of a deadly infective cause will unavoidably open room for other mortality causes.

We agree but suggest that while this remark (and related remarks) may be obvious to the reviewer, we believe that it is important to include the statement anyway.

L68. (and related sentences in the Results) This sentence is somewhat ambiguous: it is not clear whether the paper also aims to represent a model of the impact of HIV intervention on HIV itself. According to what stated here the answer seems to be \"no\", that is the role of modelling HIV seems to be purely "of service" for modelling its output on HPV. Is this correct? I understand that the model of HIV is quite oversimplified which does not make it a good model for predicting the HIV epidemics per se, but in this case one should perhaps motivate why then to model HIV at all, rather than, simply taking the most parsimonious choice namely, postulating some direct effects that HIV control measures in place in Tanzania might have for HPV circulation and eventually for progression to CC. This point should be considered carefully.

The primary focus of this manuscript is to quantify the impact that HIV prevention and control to date has already had and is anticipated to have in the future on cervical cancer incidence. So, the HIV modelling is largely "in service to" the cervical cancer incidence modelling. As cervical cancer (which can occur only in women) is the primary outcome, and cervical cancer is caused by HPV (transmitted only via sexual contact) the HIV components do not account for MSM or injection-drug users, as the impact of these on the primary outcome of this analysis is expected to be negligible. The level of detail included in the HIV components of this model are largely consistent with that of previously published models assessing elimination of HIV in Africa (PLoS Med. 2012;9(7):e1001245. doi: 10.1371/journal.pmed.1001245. Epub 2012 Jul 10). Therefore, we respectfully disagree with the statement that the HIV components of this model are "oversimplified" for the purposes of modelling cervical cancer. Nonetheless, this has been addressed as a limitation in the discussion (lines 445-447 on p32).

"Furthermore, the HIV transmission component of this model accounts for heterosexual transmission only, which is based on the assumption that the impact of HIV transmitted via sexual contact between men, and injection drug use, will have negligible impacts on the cervical cancer in women."

Model presentation is very rapid, with all details relegated to the Sup Mat. However, readers would like to have the possibility to judge about the goodness of the adopted model (it is by this goodness that we can judge the relevance of the model predictions) without the need to continuously switch to the Sup Mat. Therefore, I recommend that the part of the results that deal with the estimation of critical model parameters (basically, the "Calibration results" of Sup Mat 1) are reported in the main text in the Results section.

Thank you for pointing this out, we have made the recommended in text changes. Please see our response to comments above from the editor and reviewer 1 on this point.

Yet, the Sup Mat 1 should be better organised. There are no model equations, the demographic part is a bit unclear (seemingly the authors use a variable population, but this is totally contrasting with the idea that the population is "uniformly distributed over 5-years age groups" etc), information on mixing patterns and related references should be made clear and usable by readers.

A large proportion of the supplementary appendix has been re-located to the main text, including the re-writing the section pertaining to sexual behaviour and force of infection (starting line 146 on page 10). To clarify simulation of population demography (specifically ageing) we have re-worded some text in the subsection titled "demography" (now also in the main text). See line 127-134 p 9

"The youngest simulated age group is 5-9 years, therefore recruitment represents the number of children born who survive to age five, and accounts for the age- and year-specific fertility rates of the simulated female population, as well as infant mortality. The probability in each timestep of any individual ageing to the next five-year age-group is calculated using the number of single-year ages the age group, and the number of model iterations per year. For example, we assume that 1/5 of individuals in the 10-14 year age-group will turn 15 in any given year, and since there are four timesteps simulated per year, the probability of ageing from the 10-14 year group to the 15-19 year group is 1/5×1/4=0.05. "

Specific points

L17 "59.1 per 100,000" per year

Thank you for pointing this out, we have made the recommended in text changes (see line 17 p 2).

L18 \"the impact that intervention aimed at controlling HIV\"

Line 18-19 p 2 now reads "... to quantify the impact that interventions aimed at controlling HIV ..."

L21 It is not made clear to readers that these are the three main interventions against HIV currently in place in Tanzania.

To clarify this point, the following text has been inserted on page 5, lines 73-76.

"The two main interventions against HIV currently in place in Tanzania are ART for HIV positive individuals, and VMMC, which are both being actively scaled up(26); while the Tanzanian Ministry of Health recommends PrEP use for those at significant risk of HIV acquisition, scale up of access to PrEP has been minimal(27)."

L26 It is unclear to what the figure of 24,967 total deaths actually refers to. From the results it appears that it is the sum of prevented deaths by AIDS and CC. This should be clarified.

Thank you for pointing this out. The figure has now been defined (in Table 6) as "deaths due to HIV or cervical cancer prevented cumulatively".

L54 \"reduce HIV-1 acquisition\"? presume you mean \"hazard of acquisition\" but still is unclear, which unit are you referring to ? per single sexual act ? or what else ?

Three randomised controlled intervention trials assessed the capacity of male circumcision to prevent HIV acquisition (Auvert PLoS Med 2005; Baily Lancet 2007; Gray Lancet 2007). Here, uncircumcised men were randomised to the intervention arm (VMMC) or the control arm (no VMMC). For two of these studies the follow-up time was 24 months, and for one study the follow-up time with 18 months. The average relative reduction in risk for HIV acquisition in circumcised men found through these trials was calculated to be 60%.

To clarify the meaning of this, the text in the introduction has been altered (lines 59-61 on page 4) to read

"In particular, male circumcision has been shown to reduce the risk of HIV-1 acquisition over a time-period of 18-24 months in heterosexual men by at least 60%, and, reduce HPV prevalence among heterosexual men by 63%(15-19)."

L56 prevelance

"Prevalence" is now spelled correctly.

L64: (19) and (20) are independent studies so cit 19 should be reported after \"with HIV\"

Description "dual HIV-HPV" is often used. I suggest to use some cleared description.

The citations have now been separated (see lines 66-69 on pages 4-5).

L98 "For each scenario, we estimated HPV and HIV prevalence". At least over 2020-2070 you should say "we projected" (based on the model hypotheses)

Please see our changes to line 452-454 on page 16

"For each scenario, we estimate HPV and HIV prevalence, and cervical cancer incidence and cervical cancer mortality (stratified by HIV positivity) from 1995-2020, and project these outcomes based on model hypotheses from 2021 to 2070".

I suggest to put Table 1 in concise form avoiding long verbal descriptions (that can be put in the caption) in table entries.

We have significantly reduced the amount of text contained in this table (now called Table 3), as some of the information contained therein could have been ascertained from the following figure.

Reviewer \#3: The authors of this paper developed a deterministic transmission-dynamic model of HPV and HIV transmission, and natural history of HPV-related cervical cancer and HIV, to estimate the impact of actual and scaled-up HIV control actions on past and future trends of cervical cancer incidence and mortality in Tanzania. HIV control actions include voluntary medical male circumcision (VMMC), anti-retroviral therapy (ART), and pre-exposure prophylaxis. The model parameters were fixed based on the literature or calibrated to empirical data. Five scenarios of HIV control actions (no control, only VMMC, actual control with VMMC and ART, and three scaled-up control scenarios) were elaborated and compared in terms of cervical cancer incidence and mortality between 1995 and 2070. Age-standardized incidence of cervical cancer and mortality due to cervical cancer, number of deaths due to cervical cancers, number of cases of cervical cancer, and total number of death averted, HPV prevalence, HIV prevalence, were used as outcomes for comparison.

This study shows that interventions aimed at HIV prevention can have major indirect effect on cervical cancer. This important effect would be missed in a typical effectiveness analysis which does not include HPV infection and transmission. The authors' usage of a model of HPV/HIV transmission and development of subsequent cervical cancer is necessary if HIV infection can affect both HPV transmission and HPV natural history of disease. The mathematical model used appears adequate overall with a potential limitation regarding the grouping of HPV-genotypes (e.g., a single group for all cross-protective types). However, the calibration does not account sufficiently for the substantial parameter uncertainty related to the complicated and still uncertain interaction between HIV and HPV, and such uncertainty is not visible in the results presented. Hence, the present study requires some methodological adjustment but is a potentially important contribution to the assessment of HIV prevention effectiveness in Tanzania and other sub-Saharan countries of similar context.

Major comments

The estimation of the effect of parameters uncertainty on the results is unclear or inadequate in this study. To my understanding, two sensitivity analyses were done. In the first analysis, a subset of the parameters is varied and their impact on calibration targets is assessed: this cannot be used to estimate parameters uncertainty on the study outcomes (HIV control actions effectiveness). Even if varying a parameter does not have an impact on calibration target this does not mean that the parameter does not have an impact on effectiveness. For example, different combinations of parameter can lead to the same fit of pre intervention incidence, but produce sharp differences in post intervention effectiveness. In the second analysis, parameters related to the effect of HIV control actions (e.g., effect of circumcision on transmission) are varied and their impact on the study outcomes are ascertained, but this analysis does not include other uncertain parameters such as those related to sexual behavior. In the presentation of results, a single number is given with no uncertainty interval. It is highly unlikely that the numbers given are precise enough to justify omitting an uncertainty interval.

We thank the reviewer for this comment and have attempted to address it in the following way. We have combined the two separate sensitivity analyses into one larger sensitivity analysis, which incorporates sexual behaviour (volume of interactions for high/general activity men and women, including over-time changes and the degree of age-assortative mixing), HIV and HPV transmission (sex-specific), the impact of HIV on HPV, the impact of VMMC on HIV and HPV and the effectiveness of PrEP. This sensitivity analysis was run for all modelled scenarios (see table 5).

To present the results of this sensitivity analysis in a concise but meaningful way for the reader, figure 11 depicts the possible variation for all modelled outcomes for all scenarios in the year 2070.

The methodology of this modelling study is complex and is difficult to explain thoroughly in a short article. However, some essential information is missing and was moved to the supplementary materials: 1) information on calibration methods, 2) calibration data related to sexual behavior. Overall, although a lot of information on the methods are in Appendices, there should still be sufficient information in the core paper for readers to understand the approach and key simplifying assumptions.

We have taken this feedback on board and have moved substantial portions of the supplementary appendices to the main text (see responses above). In addition, the two separate supplementary appendices have been combined. Note that there still exists a supplementary appendix, which is now reserved for very large tables equations only.

To help understand the results, they should include the overall impact of HIV interventions partitioned as the effect due to HIV reduction only plus the secondary effect on cervical cancer. This should be done with absolute and relative measures (number of deaths and mortality rates). Presenting only the absolute number of deaths averted is insufficient. Absolute numbers can be diluted by other effects such as population growth. Presenting both relative and absolute effects allow both to understand the underlying results (relative impact) and provide numbers for policy makers (absolute). In addition, relative numbers may help with generalizability (or discussion of generalizability) of the results to other settings.

We are unable to present a breakdown of the impact due to HIV reduction only in this iteration of the model design as the HIV and HPV components are fully integrated.

To correct/account for the impact of population growth, we also present age-standardised rates (standardised to a fixed population structure and not changing over time) of cervical cancer incidence and mortality (figure 10).

The limits related to grouping HPV-genotypes should be at the minimum mentioned. Grouping HPV-types is known to produce "super-bug" in the general population. In the context of this study with an important HIV-infected population, it is not immediately clear what would be the impact of grouping genotypes. Given that people living with HIV have a high prevalence of HPV co-infections, grouping types may have an impact on results as individuals in the model cannot be co-infected by more than 3 super types (what happens with competing risks towards HPV-related disease, transmission dynamics, etc?).

Thank you for pointing this out, as it is a limitation of the model. Please see our discussion on this point which has been inserted on page 35 (lines 450-455)

"The grouping of many individual HPV genotypes in the model, for example HPV 16/18, HPV 31/33/45/52/58 (HPV H5) and a category for "other high-risk HPV types", may impact the overall simulated HPV prevalence in addition to the overall transmission dynamics of the model; for example, in this model it is impossible to discern whether individuals are infected with only one or any combination of the HPV genotypes in each simulated HPV subgroup. This may result in an overestimation of effectiveness of interventions targeted at HPV reduction"

I think more explanation of the following conclusions is needed: "These results demonstrate that HIV control measures will have a substantial effect in reducing HIV-related death in Tanzania, but will have an unintended consequence of increasing cervical cancer incidence and mortality in HIV-positive women for the next few decades, as a result of their increased life expectancy." "These findings demonstrate the importance and urgency of scaling up cervical cancer prevention programs, such as HPV vaccination and cervical screening, as well as HIV control, in order to avoid the situation that lives saved from HIV-related death are instead lost to cervical cancer."

We have clarified the concluding remarks by replacing the above with the following statement (line 469-479 p32-33)"

"While VMMC and ART can reduce the burden of cervical cancer in Tanzania in the long term, they are not sufficient to bring cervical cancer incidence beneath the threshold proposed by the WHO for cervical cancer elimination. Our finding that even under the best-case scenario the rate of cervical cancer incidence in all Tanzanian women is not reduced below 35 cases per 100,000 women per year (more than eight fold higher than the elimination threshold) demonstrates the importance and urgency of scaling up cervical cancer prevention programs, such as HPV vaccination and cervical screening, as well as HIV control, in order to avoid the situation that lives saved from HIV-related death are instead lost to cervical cancer. The WHO call for global action to eliminate cervical cancer as a public health problem is an important opportunity to galvanise and unite efforts to prevent cervical cancer in Tanzania and globally(64)."

In the results, the age-standardized mortality due to cervical cancer decreases after HIV prevention. Hence, it could be argued that HIV prevention has a positive effect on mortality rates due to cervical cancer. The increase is in absolute number of deaths due to cervical cancer, because deaths have been prevented and people are living longer. It would be good to have more discussion on this, so that readers better understand the implications. If childhood mortality is prevented, there will be more deaths among adults. If deaths are prevented among young adults, more deaths will occur among older adults, etc. Lives saved from HIV will results in substantial life years gained, which should not be mistakenly interpreted as something negative. Rather that it will have consequences on the number of cervical cancer cases, and thus provide even more justification for cervical cancer prevention. But not only for cervical cancer prevention as it will increase the number of deaths due to other prevalent diseases among people living with HIV.

We now explicitly address this point in the discussion (p 32 lines 456-457): "Finally, the findings of this study must be interpreted in the context of the lengthening life expectancy in Tanzania. With the life expectancy at birth expected to rise to 75 years in 2065-2070 (compared to 54 years in 1995-2000)(34) this will necessarily result in an increased opportunity for the development of cervical cancer (and other diseases), irrespective of additional effects due to HIV treatment."

 

Minor comments

In the No intervention scenario, condom usage declines between 2011 and 2016. However, could this be partially due to the HIV prevention measures? The authors mention that HIV prevention can affect sexual behavior and condom usage. If so, shouldn't the decline in condom usage be ignored in the No intervention scenario?

This is an interesting point, however, in this case we believe that it would be most prudent to simulate the observed data in this case. Since the objective of this paper is to investigate the effects of VMMC and ART, modifying the underlying condom usage assumptions for one scenario would confuse the effect of the target interventions. While we do include some discussion and incorporation of behavioural epidemiology in this article, it is not the main focus of this study.

In First Supplementary Appendix to the article:

P. 3, last paragraph: \"The number of high-risk sexual interactions is defined as the total number of sexual interactions which could potentially result in HIV transmission.\" This sentence needs to be re-written, unless the assumption is that low-risk sexual interaction can't result in HIV transmission.

Please note that (as per the above) the sexual behaviour and force of infection section of this manuscript has been completely re-written (and relocated to the main text). The original statement quoted above is worded incorrectly, as it is true that low-risk sexual interactions can still result in HIV transmission. Please note that (in Table 5 of the main text), we now refer to "the volume of sexual interactions possibly resulting in HIV transmission ...".
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